Evidence map›Paper›PMID 41748816›Full record

ArticleScientific reports2026

Pretreatment tumor infiltrating lymphocytes and outcome in patients with HR+/HER2- advanced breast cancer treated with CDK4/6 inhibitors.

Rosalba Torrisi, Laura Giordano, Saverio Pancetti, Carlo Carnaghi, Vera Basilico, Raffaella Palumbo, Riccardo Gerosa, Giuseppe Saltalamacchia, Maria Vita Sanò, Armando Santoro and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rosalba TorrisiIRCCS, Humanitas Research Hospital Medical Oncology and Hematology Unit, viale Manzoni 56, 20089, Rozzano, MI, Italy. roslaba.torrisi@gmail.com.
Laura GiordanoIRCCS, Humanitas Research Hospital Medical Oncology and Hematology Unit, viale Manzoni 56, 20089, Rozzano, MI, Italy.
Saverio PancettiPathology Department Rozzano, IRCCS Humanitas Research Hospital, Milano, Italy.
Carlo CarnaghiMedical Oncology Unit, Istituto Clinico Humanitas, Centro Catanese di Oncologia, Catania, Italy.
Vera BasilicoMedical Oncology Unit, Istituto Clinico Mater Domini Humanitas, Castellanza, Varese, Italy.
Raffaella PalumboOncologia Medica IRCCS ICS Maugeri, Pavia, Italy.
Riccardo GerosaIRCCS, Humanitas Research Hospital Medical Oncology and Hematology Unit, viale Manzoni 56, 20089, Rozzano, MI, Italy.
Giuseppe SaltalamacchiaIRCCS, Humanitas Research Hospital Medical Oncology and Hematology Unit, viale Manzoni 56, 20089, Rozzano, MI, Italy.
Maria Vita SanòMedical Oncology Unit, Istituto Clinico Humanitas, Centro Catanese di Oncologia, Catania, Italy.
Armando SantoroIRCCS, Humanitas Research Hospital Medical Oncology and Hematology Unit, viale Manzoni 56, 20089, Rozzano, MI, Italy.
Bethania FernandesPathology Department Rozzano, IRCCS Humanitas Research Hospital, Milano, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Growing evidence suggests that enhancement of the tumor immune response contributes to the antitumor activity of CDK4/6 inhibitors (CDK4/6i), but the role of pretreatment tumor immune microenvironment is not clear. We retrospectively investigated in patients with HR+/HER2- advanced breast cancer receiving CDK4/6i and endocrine therapy whether pretreatment stromal tumor infiltrating lymphocytes (sTILs) were associated with outcome. A total of 100 patients were evaluable 53 treated with palbociclib, 44 with ribociclib and 3 with abemaciclib. Tumors were classified as sTILs positive (sTILs+) when sTILs were ≥ 10%. 58 tumors were sTILs negative (sTILs-) and 42 sTILs+. sTILs were not associated with any outcome overall and in the ribociclib cohort. Conversely, patients treated with palbociclib and sTILs+ tumors experienced a statistically significant improved overall survival (mOS Not Reached vs. 41.1 months, p = .038) and a reduced risk of visceral progression (24 vs. 8 patients p=.0048) as compared with patients with sTILs- tumors. Pretreatment sTILs levels were associated with outcome in patients treated with palbociclib. Given the lack of interaction between treatment and sTILs our findings warrant validation in larger, independent cohorts and if confirmed propose sTILs as a simple and reproducible biomarker to aid patient selection for palbociclib.

Indexed as

Breast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Erb-b2 Receptor Tyrosine KinasesLymphocytes, Tumor-InfiltratingProtein Kinase InhibitorsAdultAgedAminopyridinesBenzimidazolesFemaleHumansMiddle AgedPiperazinesPurinesPyridinesabemaciclibAminopyridinesBenzimidazolesCDK4 protein, humanCDK6 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6ERBB2 protein, humanErb-b2 Receptor Tyrosine KinasespalbociclibPiperazinesProtein Kinase InhibitorsPurinesPyridinesReceptors, EstrogenReceptors, ProgesteroneribociclibCDK4/6 inhibitorsHR+/HER2 negative advanced breast cancerStromal tumor infiltrating lymphocytes

Identifiers

PMID41748816
PMCPMC13047036

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.